Aliases & Classifications for Spondylitis

MalaCards integrated aliases for Spondylitis:

Name: Spondylitis 12 73 54 15 70

Classifications:



External Ids:

Disease Ontology 12 DOID:6590
ICD9CM 34 720.8
SNOMED-CT 67 202651004
ICD10 32 M46
UMLS 70 C0029644 C0038012

Summaries for Spondylitis

MalaCards based summary : Spondylitis is related to juvenile ankylosing spondylitis and ankylosing spondylitis 1, and has symptoms including sciatica An important gene associated with Spondylitis is HLA-B (Major Histocompatibility Complex, Class I, B), and among its related pathways/superpathways are Innate Immune System and PAK Pathway. The drugs Adalimumab and Pamidronate have been mentioned in the context of this disorder. Affiliated tissues include bone, spinal cord and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 73 Spondylitis is an inflammation of the vertebrae. It is a form of spondylopathy. In many cases,... more...

Related Diseases for Spondylitis

Diseases related to Spondylitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1187)
# Related Disease Score Top Affiliating Genes
1 juvenile ankylosing spondylitis 32.7 TNF ERAP1
2 ankylosing spondylitis 1 32.6 HLA-B CRP
3 fibromyalgia 32.0 TNF IL6 IL10 CRP
4 spondyloarthropathy 1 31.8 TNF TAP2 TAP1 NOD2 IL6 IL23R
5 kummell's disease 31.5 SOST DKK1
6 spondylarthropathy 31.4 TNF HLA-B
7 spinal disease 31.2 TNF IL6 IL17A ERAP1 CRP CCR6
8 iridocyclitis 31.1 TNF IL6 IL17A IL10 HLA-B CRP
9 enthesopathy 31.1 TNF ERAP1 CRP CCR6
10 uveitis 31.0 TNF NOD2 LTA IL6 IL17A IL10
11 brucellosis 30.9 TNF IL6 IL17A IL10 CRP
12 ankylosis 30.9 TNF SOST IL17A CCR6
13 arthropathy 30.9 TNF MICA LTA IL6 HLA-B CRP
14 psoriatic arthritis 30.9 TNF NOD2 MICA LTA IL6 IL23R
15 juvenile rheumatoid arthritis 30.9 TNF LTA IL6 IL10 CRP
16 pustulosis of palm and sole 30.9 TNF IL17A CRP CCR6
17 spondyloarthropathy 30.9 TNF LTA IL6 IL17A IL10 HLA-C
18 osteomyelitis 30.9 TNF NOD2 IL6 IL10 CRP
19 bursitis 30.9 TNF IL6 CRP
20 aortitis 30.8 TNF IL6 IL17A CRP
21 vasculitis 30.7 TNF IL6 IL17A HLA-B CRP
22 osteoarthritis 30.7 TNF IL6 IL17A CRP
23 radiculopathy 30.6 IL6 IL17A IL10
24 tendinitis 30.6 TNF IL6 CRP
25 aortic aneurysm, familial abdominal, 1 30.5 TNF IL6 IL10 CRP
26 myositis 30.5 TNF IL6 IL17A HLA-B
27 endocarditis 30.5 TNF IL6 IL17A IL10 CRP
28 lung disease 30.5 TNF IL6 IL17A IL10 CRP
29 fasciitis 30.5 TNF LTA IL6
30 neutropenia 30.5 TNF IL6 IL10 CRP
31 rheumatic fever 30.5 TNF IL6 IL10
32 conjunctivitis 30.4 TNF IL6 IL10 HLA-B
33 urethritis 30.4 TNF IL6 IL10 CRP
34 periodontitis 30.4 TNF IL6 IL17A IL10 CRP
35 pericarditis 30.4 TNF IL6 CRP
36 chlamydia 30.4 TNF IL6 IL17A IL10 CRP
37 sleep apnea 30.4 TNF IL6 IL10 CRP
38 neuritis 30.4 TNF LTA IL6 IL10
39 skeletal tuberculosis 30.4 TNF CRP
40 end stage renal disease 30.4 TNF IL6 IL10 CRP
41 reactive arthritis 30.4 TNF IL6 IL17A IL10 HLA-B CRP
42 rheumatoid arthritis 30.4 TNF LTA IL6 IL23R IL17A IL10
43 interstitial lung disease 30.4 TNF IL6 IL17A IL10 CRP
44 toxoplasmosis 30.3 TNF IL6 IL10
45 mixed connective tissue disease 30.3 TNF IL6 IL10
46 prostatitis 30.3 TNF IL6 IL17A IL10
47 infective endocarditis 30.3 TNF IL6 IL17A CRP
48 familial mediterranean fever 30.3 TNF NOD2 IL6 IL17A IL10 CRP
49 proteasome-associated autoinflammatory syndrome 1 30.3 TNF IL6 IL17A IL10 CRP
50 optic neuritis 30.3 TNF LTA IL6 IL10

Comorbidity relations with Spondylitis via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Spondylitis:



Diseases related to Spondylitis

Symptoms & Phenotypes for Spondylitis

UMLS symptoms related to Spondylitis:


sciatica

GenomeRNAi Phenotypes related to Spondylitis according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.55 MICA
2 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.55 HLA-B HLA-C
3 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.55 MICA
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.55 HLA-C
5 Increased shRNA abundance (Z-score > 2) GR00366-A-139 9.55 MICA
6 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.55 HLA-C
7 Increased shRNA abundance (Z-score > 2) GR00366-A-162 9.55 HLA-C
8 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.55 NOD2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.55 NOD2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.55 MICA
11 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.55 HLA-C
12 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.55 MICA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.55 HLA-B HLA-C
14 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.55 MICA
15 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.55 HLA-C

MGI Mouse Phenotypes related to Spondylitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.93 ANTXR2 CCR6 ERAP1 IL10 IL17A IL23R
2 immune system MP:0005387 9.77 ANTXR2 CCR6 CRP ERAP1 IL10 IL17A
3 skeleton MP:0005390 9.32 DKK1 ERAP1 IL10 IL17A IL6 LTA

Drugs & Therapeutics for Spondylitis

Drugs for Spondylitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 129)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adalimumab Approved, Experimental Phase 4 331731-18-1 16219006
2
Pamidronate Approved Phase 4 40391-99-9 4674
3
Loxoprofen Approved Phase 4 68767-14-6, 80382-23-6 3965
4
Aceclofenac Approved, Investigational Phase 4 89796-99-6 71771
5
Sulfasalazine Approved Phase 4 599-79-1 5359476 5353980
6
Hydroxychloroquine Approved Phase 4 118-42-3 3652
7
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
8
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 5281106 54677470
9
Etanercept Approved, Investigational Phase 4 185243-69-0
10
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
11
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
12
Acetaminophen Approved Phase 4 103-90-2 1983
13
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
14
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
15 Natriuretic Peptide, Brain Phase 4
16 Anti-Infective Agents Phase 4
17 Mitogens Phase 4
18 Endothelial Growth Factors Phase 4
19 Cholestyramine Resin Phase 4
20 Tripterygium Phase 4
21 Antibodies Phase 4
22 Immunoglobulins Phase 4
23 Antibodies, Monoclonal Phase 4
24 Antimalarials Phase 4
25 Antiparasitic Agents Phase 4
26 Antiprotozoal Agents Phase 4
27 Analgesics, Non-Narcotic Phase 4
28 Analgesics Phase 4
29 Anti-Inflammatory Agents Phase 4
30 Anti-Inflammatory Agents, Non-Steroidal Phase 4
31 Cyclooxygenase Inhibitors Phase 4
32 Cyclooxygenase 2 Inhibitors Phase 4
33 Narcotics Phase 4
34 Analgesics, Opioid Phase 4
35 Antipyretics Phase 4
36 Tocolytic Agents Phase 4
37
Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
38
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
39
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
40
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
41
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
42
Apremilast Approved, Investigational Phase 3 608141-41-9 11561674
43
Naproxen Approved, Vet_approved Phase 3 22204-53-1 1302 156391
44
Etoricoxib Approved, Investigational Phase 3 202409-33-4 123619
45
Certolizumab pegol Approved Phase 3 428863-50-7
46
Rebamipide Approved, Investigational Phase 3 90098-04-7
47
Misoprostol Approved Phase 3 59122-46-2 5282381
48
tannic acid Approved Phase 3 1401-55-4
49
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
50
Ustekinumab Approved, Investigational Phase 3 815610-63-0

Interventional clinical trials:

(show top 50) (show all 360)
# Name Status NCT ID Phase Drugs
1 A Multicenter,Double-Blind and Randomized Controlled Trial of Fengshigutong Capsule in the Treatment of Ankylosing Spondylitis Unknown status NCT03932006 Phase 4 Fengshigutong Capsule plus Imrecoxib;Fengshigutong Capsule;Imrecoxib
2 Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study Unknown status NCT02489760 Phase 4
3 Combined Treatment With TNF (Tumor Necrosis Factor) Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression Unknown status NCT02313727 Phase 4 Pamidronate
4 TReat-to-tArget (T2T) With seCukinumab in Axial Spondyloarthritis. IdEntification of MRI and Biochemical Biomarkers for Disease Activity, Treatment Response and Structural Damage Progression (the TRACE Study) Unknown status NCT03639740 Phase 4 Secukinumab 150 milligram [Cosentyx]
5 Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
6 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
7 Efficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing Spondylitis Unknown status NCT02638896 Phase 4 etanercept (Half-Dose);etanercept (Full-Dose);Sulfasalazine;Celecoxib
8 The Efficacy of Adalimumab and Conventional Antirheumatic Drugs in Alleviating Axial and Aortic Inflammation Detected in PET/CT in Patients With Axial Spondyloarthritis Unknown status NCT02634541 Phase 4 Adalimumab
9 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis After 16 Weeks of Treatment Compared to Placebo and to Assess the Safety, Tolerability and Efficacy up to 52 Weeks Completed NCT02798211 Phase 4 Secukinumab 300 mg;Secukinumab 150 mg
10 Evaluation of Clinical Value of Standardized Protocol for Dose-reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Therapy: Open-label, Controlled, Randomized, Multicenter Trial. Completed NCT01604629 Phase 4 Reduced doses of anti-TNF;Stable doses of anti-TNF
11 Efficacy and Safety of Loxoprofen Hydrogel Patch Versus Loxoprofen Tablet in Patients With Ankylosing Spondylitis: a 4-week Randomized, Open-label Study Completed NCT03800797 Phase 4 Loxoprofen sodium hydrogel patch;Loxoprofen sodium tablet
12 Multicentre, Open-Labeled Study Of Etanercept In The Treatment Of Patients With Ankylosing Spondylitis Completed NCT00458185 Phase 4 etanercept
13 An Open-Label Multicentre Long-Term Extension Study of Etanercept in Ankylosing Spondylitis Completed NCT00444340 Phase 4 Enbrel (Etanercept)
14 The Efficacy of Combination Methotrexate and Infliximab in Patients With Ankylosing Spondylitis:A Clinical and Magnetic Resonance Imaging Correlation Completed NCT00432432 Phase 4 Infliximab and MTX
15 An Open-label, Multicentre, Supplementary Extension Study of Etanercept in Subjects With Ankylosing Spondylitis Completed NCT00410046 Phase 4 Enbrel (etanercept)
16 TNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study of New Methods for Better Monitoring and Prognostifying Patients With Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
17 A Twelve Week, Randomized, Double Blind Parallel Group Study Of Two Doses Of Celecoxib Compared To Diclofenac In Patients With Ankylosing Spondylitis Completed NCT02528201 Phase 4 Celecoxib 200 milligrams;Celecoxib 400 milligrams;diclofenac 50 milligrams
18 Biomarkers Identification of Anti-TNF α Agent's Efficacy in Ankylosing Spondylitis Patients Using a Transcriptome Analysis and Mass Spectrometry Completed NCT02492217 Phase 4 Adalimumab
19 Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) Completed NCT01895764 Phase 4 Adalimumab;Methotrexate
20 A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept in the Treatment of Adult Patients With Active, Severe, and Advanced Axial Ankylosing Spondylitis Completed NCT00420238 Phase 4 Etanercept (Enbrel)
21 A MULTICENTER OPEN-LABEL STUDY OF ETANERCEPT WITHDRAWAL AND RETREATMENT IN SUBJECTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WHO ACHIEVED ADEQUATE 24 WEEK RESPONSE Completed NCT02509026 Phase 4
22 Effect of Methotrexate on the Relation Dose-effect of Infliximab in Ankylosing Spondylitis Completed NCT00507403 Phase 4 infliximab
23 A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab (AIN457) to Examine the Clinical Efficacy and the NSAID-sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis (ASTRUM) Completed NCT02763046 Phase 4 Secukinumab (AIN457) 150 mg s.c.;Secukinumab (AIN457) 150 mg s.c.;Placebo - Secukinumab (AIN457) 150 mg s.c.
24 Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis: a Prospective, Randomized Multicentric Study on Disease Activity Guided Etanercept Tapering or Discontinuation Completed NCT03880968 Phase 4 tapering or discontinuation of etanercept
25 A Randomized, Double-Blind Study Evaluating the Safety and Efficacy of Etanercept and Sulphasalazine in Subjects With Ankylosing Spondylitis Completed NCT00247962 Phase 4 etanercept;sulphasalazine (SSZ)
26 Effect of Anti-TNF(Alpha)Treatment on Circulating Endothelial Progenitor Cells (EPCs) and Vascular Stiffness in AS Completed NCT01212653 Phase 4 Simponi
27 Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
28 COmparison of the Effect of Treatment With NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of StrUctural Damage in the Spine Over Two Years in Patients With ankyLosing Spondylitis: a Randomized Controlled Multicentre Trial Completed NCT02758782 Phase 4 Celecoxib
29 Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment Compared to Healthy Controls Completed NCT00778869 Phase 4
30 Baseline Serum Vascular Endothelial Growth Factor (VEGF) Concentration as Predictive Factor of Response to Infliximab (Remicade) Therapy in Patients With Active Ankylosing Spondylitis Despite Conventional Treatment: a Multicenter Pilot Study Completed NCT00779935 Phase 4
31 A Multi-center, Open Label, Random Clinical Trial of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis Completed NCT01934933 Phase 4 celebrex;Enbrel;Enbrel plus Celebrex
32 A 12-week Randomized, Double-blind, Multicenter Pilot Study to Evaluate the Effect of Etanercept 100 mg and 50 mg Weekly in Subjects With Ankylosing Spondylitis Completed NCT00873730 Phase 4 etanercept;etanercept/placebo
33 Post-Registration Open-Label, Non-Comparative, Multicenter Study of Rate of Efficacy and Tolerance of the Use of Anti-TNF Chimeric Monoclonal Antibodies (Remicade) in Treatment of Patients With Active Ankylosing Spondylitis Completed NCT00779012 Phase 4
34 Effects of NSAIDs on RAdiographic Damage in Ankylosing Spondylitis (ENRADAS) - a Prospective Randomised Controlled Trial Completed NCT00715091 Phase 4 diclophenac;diclophenac
35 Chung Shan Medical University Hospital, Taiwan Completed NCT00647517 Phase 4 Ultracet
36 Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Three Years' Following-up Study Completed NCT02915354 Phase 4 Etanercept
37 An Open Trial to Evaluate the Efficacy and Safety of Infliximab(Remicade) in Treating Patients With Early Ankylosing Spondylitis Completed NCT00936143 Phase 4 infliximab
38 Total Glucosides Paeony Capsules in Maintaining Clinical Remission in Patients With Ankylosing Spondylitis Which Achieve Clinical Remission After Anti-TNF Therapy Completed NCT01517620 Phase 4 Total Glucosides Paeony Capsules
39 Open-Label, Phase 4 Study, Investigating the Incidence of Extra-Articular Manifestations in Subjects With Ankylosing Spondylitis Treated With Golimumab; Protocol No. MK-8259-012 Completed NCT01668004 Phase 4
40 Sequential Application of Yisaipu® and Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Treating Mild-to-Moderate Ankylosing Spondylitis: the Mid-term Follow-up Result Completed NCT03411798 Phase 4 Yisaipu®
41 A Clinical Trial About the Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis: a 12-week, Multi-center, Randomized, Double-blind, Active Drug and Placebo Compared Clinical Trial Completed NCT00953979 Phase 4 kunxian capsule
42 A Phase-IV, Multicenter, Noncomparative, Open-Label Study Evaluating the Safety and Efficacy of Golimumab (a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously) in the Treatment of Indian Patients With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis Recruiting NCT03733925 Phase 4 Golimumab
43 A Randomized, Double-blind, Parallel-group, Multicenter Study of Secukinumab to Compare 300 mg and 150 mg at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During an Initial 16 Weeks of Open-label Treatment With Secukinumab 150 mg (ASLeap) Active, not recruiting NCT03350815 Phase 4 150 mg open-label secukinumab;150 mg double-blinded secukinumab;300 mg double-blinded secukinumab
44 Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs, a Prospective Randomized Controlled Study Not yet recruiting NCT04077957 Phase 4 Methotrexate;Sulfasalazine;Hydroxychloroquine;Etanercept (50mg per week, for 4 weeks);Etanercept (50mg per week, for 2 weeks);Etanercept (50mg per week)
45 Effects of Etanercept on Endothelial Function and Carotid Intima-media Thickness (IMT) in Patients With Active AS Terminated NCT00910273 Phase 4 etanercept
46 A Study to Evaluate the Clinical Benefits of Tramadol/Acetaminophen (Ultracet®) vs. Diclofenac (Voltaren®) in the Treatment of Pain in Patients With Ankylosing Spondylitis Receiving Stable Treatment of Disease Modifying Anti-rheumatic Drugs (DMARDs) Terminated NCT00766402 Phase 4 Tramadol /acetaminophen;Diclofenac
47 Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis: a Pilot Study Terminated NCT03473665 Phase 4 Indomethacin;Diclofenac;Meloxicam;Celecoxib
48 Study of Peripheral Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab Terminated NCT00686894 Phase 4 Infliximab
49 A Randomized Multicentre Clinical Trial Comparing The Metal on Metal Hip System Versus The Metal on Highly Crossed Linked Polyethylene System Terminated NCT01422564 Phase 4
50 Methotrexate in the Treatment of Axial Spondyloarthritis. A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study. Withdrawn NCT00298012 Phase 4 Methotrexate

Search NIH Clinical Center for Spondylitis

Genetic Tests for Spondylitis

Anatomical Context for Spondylitis

MalaCards organs/tissues related to Spondylitis:

40
Bone, Spinal Cord, T Cells, Endothelial, Skin, Bone Marrow, Eye

Publications for Spondylitis

Articles related to Spondylitis:

(show top 50) (show all 17341)
# Title Authors PMID Year
1
Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease. 54 61
15308523 2004
2
Animal models of inflammatory spinal and sacroiliac joint diseases. 61 54
12951872 2003
3
Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience. 61
33655421 2021
4
Nonpharmacologic Pain Management in Inflammatory Arthritis. 61
33781495 2021
5
Insights into the pathogenesis of psoriatic arthritis from genetic studies. 61
33712923 2021
6
Comparison of disease activity in patients with ankylosing spondylitis under TNFi or NSAID treatment, is there any difference? An observational study. 61
31558361 2021
7
Non-radiographic axial spondyloarthritis in Tunisia: main characteristics and detailed comparison with ankylosing spondylitis. 61
32974836 2021
8
Rheumatoid arthritis coexisting with ankylosing spondylitis: A report of 22 cases with delayed diagnosis. 61
33787586 2021
9
Effects of water therapy on disease activity, functional capacity, spinal mobility and severity of pain in patients with ankylosing spondylitis: a systematic review and meta-analysis. 61
31355676 2021
10
Effectiveness and safety of anti-TNF therapy for ankylosing spondylitis: a real-world study. 61
33728937 2021
11
SASDAS: a practical tool to measure disease activity in axSpa patients. Comments on "a prospective study of novel disease activity indices for ankylosing spondylitis". 61
33427918 2021
12
The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial. 61
32926247 2021
13
Characteristics and outcome of a first acute myocardial infarction in patients with ankylosing spondylitis. 61
32845439 2021
14
Aberrant antigen processing and presentation: Key pathogenic factors leading to immune activation in Ankylosing spondylitis. 61
33532928 2021
15
Exploring simplified disease activity indices in Ankylosing Spondylitis in different populations is the need of the hour. 61
33591371 2021
16
Ankylosing spondylitis rehabilitation publications and the global productivity: a Web of Science-based bibliometric analysis (2000-2019). 61
33797569 2021
17
IFNA1 and IFNA13 Genes Confer Genetic Predisposition to Ankylosing Spondylitis-Associated Uveitis in a Chinese Population. 61
32990094 2021
18
Associations of toll-like receptor 4 and 2 gene polymorphisms with susceptibility to ankylosing spondylitis: A meta-analysis. 61
33369094 2021
19
Impact of assessing patient-reported outcomes with mobile apps on patient-provider interaction. 61
33811177 2021
20
Sex differences in brain modular organization in chronic pain. 61
33044396 2021
21
The enigmatic role of HLA-B*27 in spondyloarthritis pathogenesis. 61
33481054 2021
22
Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis: A retrospective study. 61
33787605 2021
23
Cytokine "fine tuning" of enthesis tissue homeostasis as a pointer to spondyloarthritis pathogenesis with a focus on relevant TNF and IL-17 targeted therapies. 61
33544244 2021
24
Value of serum collagen triple helix repeat containing-1(CTHRC1) and 14-3-3η protein compared to anti-CCP antibodies and anti-MCV antibodies in the diagnosis of rheumatoid arthritis. 61
32813981 2021
25
Enthesitis may be one of the signs of severe disease in familial Mediterranean fever. 61
32920724 2021
26
The usefulness and validity of English-language videos on YouTube as an educational resource for spondyloarthritis. 61
32880051 2021
27
Fibromyalgia in patients with synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome: prevalence and screening. 61
32949312 2021
28
Reviewing disease activity indices in spondyloarthritis from the gender perspective: A systematic review and meta-analysis. 61
33795327 2021
29
The structural, functional and electrophysiological assessment of paraspinal musculature of patients with ankylosing spondylitis and non-radiographic axial spondyloarthropathy. 61
33502552 2021
30
Treatment patterns and health care resource utilization among Japanese patients with ankylosing spondylitis: A hospital claims database analysis. 61
32476522 2021
31
Biomechanical influence of the surgical approaches, implant length and density in stabilizing ankylosing spondylitis cervical spine fracture. 61
33727613 2021
32
Circulating miR-145 as a marker of therapeutic response to anti-TNF therapy in patients with ankylosing spondylitis. 61
33676382 2021
33
Gut microbiota changes in inflammatory bowel diseases and ankylosing spondilytis. 61
33548121 2021
34
The influence of the SARS-CoV-2 lockdown on patients with inflammatory rheumatic diseases on their adherence to immunomodulatory medication - a cross sectional study over 3 months in Germany. 61
33704418 2021
35
Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review. 61
33595833 2021
36
Changes in bone formation regulator biomarkers in early axial spondyloarthritis. 61
32888036 2021
37
RxIALTA: evaluating the effect of a pharmacist-led intervention on CV risk in patients with chronic inflammatory diseases in a community pharmacy setting: a prospective pre-post intervention study. 61
33762234 2021
38
Efficacy and safety of interleukin-17 inhibitors in the treatment of chronic rheumatic diseases: A combined and updated meta-analysis. 61
33768576 2021
39
Successful use of tofacitinib in the treatment of diffuse systemic sclerosis and axial spondyloarthritis: a case-based review. 61
33433730 2021
40
Metabolomic analysis of biochemical changes in the tissue and urine of proteoglycan-induced spondylitis in mice after treatment with moxibustion. 61
32953451 2021
41
Validity, reliability, and factor structure of the Istanbul Low Back Pain Disability Index in axial spondyloarthritis. 61
32075459 2021
42
Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study. 61
33650469 2021
43
Atorvastatin combined with low-dose dexamethasone for vascular endothelial cell dysfunction induced by chronic subdural hematoma. 61
32985481 2021
44
Treatment of single-segment suppurative spondylitis with the transforaminal endoscopic focal cleaning and drainage. 61
31180827 2021
45
Epidemiology of 2000 Chinese uveitis patients from Northeast China. 61
32424058 2021
46
A diagnostic model for differentiating tuberculous spondylitis from pyogenic spondylitis on computed tomography images. 61
33768287 2021
47
Psoriasis-Arthritis und ankylosierende Spondylitis. 61
33710581 2021
48
Culture-negative versus culture-positive in pyogenic spondylitis and analysis of risk factors for relapse. 61
33683182 2021
49
The management of neglected spondylitis tuberculosis with dislocated C1 and C2 odontoid destruction: A case report. 61
33609945 2021
50
Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. 61
33740465 2021

Variations for Spondylitis

Expression for Spondylitis

Search GEO for disease gene expression data for Spondylitis.

Pathways for Spondylitis

Pathways related to Spondylitis according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.75 TNF TAP2 TAP1 NOD2 MICA LTA
2
Show member pathways
13.25 TNF LTA IL6 IL23R IL17A IL10
3
Show member pathways
13.24 TNF NOD2 LTA IL6 IL23R IL17A
4
Show member pathways
12.85 TNF TAP2 TAP1 MICA IL6 HLA-C
5
Show member pathways
12.76 TNF TAP2 TAP1 IL6 HLA-C HLA-B
6 12.7 TNF TAP2 TAP1 LTA IL6 HLA-C
7
Show member pathways
12.54 TNF IL6 IL23R IL17A IL10
8 12.52 TNF TAP2 TAP1 IL17A IL10
9
Show member pathways
12.51 TNF NOD2 IL6 IL23R IL17A IL10
10
Show member pathways
12.4 TNF TAP2 TAP1 MICA LTA IL6
11 12.29 TNF LTA IL6 HLA-C HLA-B
12
Show member pathways
12.27 TNF LTA IL6 IL10 CCR6
13 12.2 TNF NOD2 IL6 ANTXR2
14 12.19 TNF NOD2 IL6 IL10
15
Show member pathways
12.16 TNF LTA IL6 IL17A IL10 HLA-C
16 12.1 TAP2 TAP1 HLA-C HLA-B
17 11.91 TNF NOD2 LTA IL6
18 11.89 TNF IL6 IL23R IL17A IL10
19 11.71 TNF IL6 IL10
20 11.69 TNF IL6 IL10
21
Show member pathways
11.65 TNF LTA IL6 IL17A IL10
22 11.54 TNF LTA IL6 IL10 CCR6
23 11.54 TNF LTA IL23R IL17A IL10 CCR6
24 11.5 TNF IL6 IL10
25 11.49 TNF IL6 IL10
26 11.34 TNF IL6 IL10
27 11.31 TNF IL6 IL10
28 11.27 TNF IL6 IL17A
29 11.21 TNF IL6 IL10
30 10.98 TNF IL6 CRP
31 10.5 TAP2 TAP1 HLA-C HLA-B ERAP2 ERAP1

GO Terms for Spondylitis

Cellular components related to Spondylitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.02 TNF SOST LTA IL6 IL17A IL10
2 endoplasmic reticulum membrane GO:0005789 9.91 TAP2 TAP1 HLA-C HLA-B ERAP2 ERAP1
3 extracellular space GO:0005615 9.85 TNF SOST MICA LTA IL6 IL17A
4 external side of plasma membrane GO:0009897 9.8 TNF MICA IL23R IL17A CCR6
5 MHC class I protein complex GO:0042612 9.46 HLA-C HLA-B
6 MHC class I peptide loading complex GO:0042824 9.43 TAP2 TAP1
7 TAP complex GO:0042825 9.26 TAP2 TAP1
8 phagocytic vesicle membrane GO:0030670 9.26 TAP2 TAP1 HLA-C HLA-B
9 cell surface GO:0009986 9.17 TNF NOD2 MICA HLA-C HLA-B CCR6

Biological processes related to Spondylitis according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 10.08 NOD2 IL23R IL17A HLA-C HLA-B CRP
2 inflammatory response GO:0006954 10.04 TNF IL6 IL23R IL17A CRP
3 cytokine-mediated signaling pathway GO:0019221 9.99 TNF IL6 IL23R IL17A IL10
4 adaptive immune response GO:0002250 9.98 TAP2 TAP1 IL17A HLA-C HLA-B ERAP2
5 immune system process GO:0002376 9.97 TAP2 TAP1 NOD2 IL23R IL17A HLA-C
6 response to lipopolysaccharide GO:0032496 9.93 NOD2 LTA IL23R IL10
7 cellular response to lipopolysaccharide GO:0071222 9.92 TNF NOD2 IL6 IL10
8 defense response GO:0006952 9.91 TNF TAP1 NOD2 HLA-B
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 TNF IL6 IL23R
10 response to glucocorticoid GO:0051384 9.85 TNF IL6 IL10
11 positive regulation of interleukin-6 production GO:0032755 9.85 TNF NOD2 IL6 IL17A
12 positive regulation of interferon-gamma production GO:0032729 9.83 TNF LTA IL23R
13 positive regulation of interleukin-8 production GO:0032757 9.82 TNF NOD2 IL6
14 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.81 TAP2 TAP1 HLA-C HLA-B
15 humoral immune response GO:0006959 9.8 TNF LTA IL6 CCR6
16 positive regulation of interleukin-1 beta production GO:0032731 9.78 TNF NOD2 IL6 IL17A
17 positive regulation of interleukin-12 production GO:0032735 9.77 NOD2 IL23R IL17A
18 positive regulation of JAK-STAT cascade GO:0046427 9.76 TNF IL6 IL10
19 positive regulation of osteoclast differentiation GO:0045672 9.73 TNF IL23R IL17A
20 defense response to Gram-positive bacterium GO:0050830 9.73 TNF NOD2 LTA IL6 IL17A CRP
21 positive regulation of glial cell proliferation GO:0060252 9.71 TNF LTA IL6
22 positive regulation of interleukin-17 production GO:0032740 9.7 NOD2 IL6 IL23R
23 peptide transport GO:0015833 9.68 TAP2 TAP1
24 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.67 HLA-C HLA-B
25 endothelial cell apoptotic process GO:0072577 9.67 TNF IL10
26 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.67 TNF NOD2 IL6 IL17A
27 response to peptidoglycan GO:0032494 9.66 NOD2 IL6
28 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent GO:0002486 9.66 HLA-C HLA-B
29 vascular endothelial growth factor production GO:0010573 9.65 TNF IL6
30 vesicle fusion with endoplasmic reticulum-Golgi intermediate compartment (ERGIC) membrane GO:1990668 9.64 TAP2 TAP1
31 negative regulation of cytokine production involved in immune response GO:0002719 9.63 TNF IL10
32 negative regulation of lipid storage GO:0010888 9.63 TNF IL6 CRP
33 negative regulation of interleukin-18 production GO:0032701 9.62 NOD2 IL10
34 immune response GO:0006955 9.61 TNF MICA LTA IL6 IL17A IL10
35 cytosol to ER transport GO:0046967 9.58 TAP2 TAP1
36 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.58 TNF NOD2 LTA
37 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.57 TNF LTA
38 antigen processing and presentation of endogenous peptide antigen via MHC class I GO:0019885 9.46 TAP2 TAP1 ERAP2 ERAP1
39 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.1 TAP2 TAP1 HLA-C HLA-B ERAP2 ERAP1

Molecular functions related to Spondylitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interleukin-6 receptor binding GO:0005138 9.46 IL6 ERAP1
2 TAP1 binding GO:0046978 9.43 TAP2 TAP1
3 MHC class Ib protein binding GO:0023029 9.4 TAP2 TAP1
4 peptide antigen-transporting ATPase activity GO:0015433 9.37 TAP2 TAP1
5 cytokine activity GO:0005125 9.35 TNF LTA IL6 IL17A IL10
6 peptide transmembrane transporter activity GO:1904680 9.32 TAP2 TAP1
7 peptide-transporting ATPase activity GO:0015440 9.26 TAP2 TAP1
8 TAP binding GO:0046977 9.16 HLA-C HLA-B
9 peptide antigen binding GO:0042605 8.92 TAP2 TAP1 HLA-C HLA-B

Sources for Spondylitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....